Replies to post #202522 on Biotech Values

[DewDiligence]

EGRX—Can you elaborate on why MDCO en banc outcome is bullish for Kangio?

The CAFC ruling (upholding MDCO's patents on Angiomax) keeps generic versions of Angiomax off the US market. EGRX's Kangio will therefore have to compete only with MDCO's branded Angiomax when it enters the US market (pending FDA approval).

EGRX was not sued by MDCO wrt Kangio because it was clear that Kangio does not infringe MDCO's patents.